Search research articles
Contact Us
Filters
Showing results (51-60 of 136) with videos related to
Page
of 14
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 6, 2018
Targeting <i>BRAF</i> Mutations in High-Grade Neuroendocrine Carcinoma of the Colon
Jarred Burkart, Dwight Owen, Manisha H Shah, et al.
Cancers
|
June 13, 2025
Effect of Intolerance of Uncertainty on Perceived Cognitive Function Among Breast Cancer Patients Before Chemotherapy
Yesol Yang, Alai Tan, Sagar D Sardesai, et al.
Frontiers in Oncology
|
May 25, 2026
Management of bone metastases in patients with breast cancer: review of bone-modifying therapy, emerging new agents, and future directions
Gilbert Bader, Brianna Brown, Ashley Pariser Davenport, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2024
A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas
Olivier Rixe, John L Villano, Robert Wesolowski, et al.
Journal of Cancer Survivorship : Research and Practice
|
January 15, 2020
Cognitive problems of breast cancer survivors on proton pump inhibitors
Annelise A Madison, Alex Woody, Brittney Bailey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2021
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
Aditya Bardia, Virginia Kaklamani, Sharon Wilks, et al.
Cardio-Oncology (London, England)
|
December 9, 2020
Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
Sagar Sardesai, Jasmine Sukumar, Mahmoud Kassem, et al.
Cancer Control : Journal of the Moffitt Cancer Center
|
May 27, 2024
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Dionisia Quiroga, Robert Wesolowski, Sara Zelinskas, et al.
Cancer Chemotherapy and Pharmacology
|
February 23, 2013
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
Rachel M Layman, Amy S Ruppert, Melinda Lynn, et al.
Clinical Breast Cancer
|
August 28, 2019
Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer
Jonathan Wilkie, M Alexandra Schickli, Michael J Berger, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 136) with videos related to
Sort By:
Page
of 14
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 6, 2018
Targeting <i>BRAF</i> Mutations in High-Grade Neuroendocrine Carcinoma of the Colon
Jarred Burkart, Dwight Owen, Manisha H Shah, et al.
Cancers
|
June 13, 2025
Effect of Intolerance of Uncertainty on Perceived Cognitive Function Among Breast Cancer Patients Before Chemotherapy
Yesol Yang, Alai Tan, Sagar D Sardesai, et al.
Frontiers in Oncology
|
May 25, 2026
Management of bone metastases in patients with breast cancer: review of bone-modifying therapy, emerging new agents, and future directions
Gilbert Bader, Brianna Brown, Ashley Pariser Davenport, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 12, 2024
A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas
Olivier Rixe, John L Villano, Robert Wesolowski, et al.
Journal of Cancer Survivorship : Research and Practice
|
January 15, 2020
Cognitive problems of breast cancer survivors on proton pump inhibitors
Annelise A Madison, Alex Woody, Brittney Bailey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 29, 2021
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
Aditya Bardia, Virginia Kaklamani, Sharon Wilks, et al.
Cardio-Oncology (London, England)
|
December 9, 2020
Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
Sagar Sardesai, Jasmine Sukumar, Mahmoud Kassem, et al.
Cancer Control : Journal of the Moffitt Cancer Center
|
May 27, 2024
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Dionisia Quiroga, Robert Wesolowski, Sara Zelinskas, et al.
Cancer Chemotherapy and Pharmacology
|
February 23, 2013
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer
Rachel M Layman, Amy S Ruppert, Melinda Lynn, et al.
Clinical Breast Cancer
|
August 28, 2019
Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer
Jonathan Wilkie, M Alexandra Schickli, Michael J Berger, et al.
Page
of 14